Ameritas Investment Partners Inc. Sells 46 Shares of Humana Inc. (NYSE:HUM)

Ameritas Investment Partners Inc. lowered its stake in shares of Humana Inc. (NYSE:HUM) by 3.4% in the first quarter, Holdings Channel reports. The firm owned 1,322 shares of the insurance provider’s stock after selling 46 shares during the period. Ameritas Investment Partners Inc.’s holdings in Humana were worth $458,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in HUM. Raymond James & Associates boosted its position in Humana by 28.7% during the fourth quarter. Raymond James & Associates now owns 101,251 shares of the insurance provider’s stock worth $46,354,000 after purchasing an additional 22,550 shares during the period. CVA Family Office LLC bought a new stake in shares of Humana in the fourth quarter valued at approximately $86,000. Raymond James Financial Services Advisors Inc. boosted its position in shares of Humana by 13.8% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 19,676 shares of the insurance provider’s stock valued at $9,008,000 after acquiring an additional 2,390 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Humana by 2.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,250 shares of the insurance provider’s stock valued at $1,946,000 after acquiring an additional 109 shares during the period. Finally, Ritholtz Wealth Management boosted its position in shares of Humana by 504.3% in the fourth quarter. Ritholtz Wealth Management now owns 4,901 shares of the insurance provider’s stock valued at $2,244,000 after acquiring an additional 4,090 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of HUM stock traded up $1.68 during trading hours on Wednesday, hitting $387.55. 507,057 shares of the company’s stock were exchanged, compared to its average volume of 1,744,044. The stock’s 50-day moving average is $363.52 and its 200-day moving average is $347.00. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. The stock has a market cap of $46.70 billion, a price-to-earnings ratio of 24.13, a price-to-earnings-growth ratio of 2.23 and a beta of 0.51. Humana Inc. has a 52 week low of $298.61 and a 52 week high of $530.54.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $9.38 earnings per share. As a group, research analysts forecast that Humana Inc. will post 16.27 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on HUM shares. Oppenheimer reduced their price objective on Humana from $415.00 to $370.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Truist Financial increased their price objective on Humana from $355.00 to $400.00 and gave the company a “hold” rating in a research report on Monday, July 15th. Barclays reduced their price objective on Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. Piper Sandler assumed coverage on Humana in a research note on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 target price for the company. Finally, Wells Fargo & Company cut their target price on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research note on Monday, April 8th. Fourteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $402.60.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.